A Manufacturing and Control Strategy to Minimize Spacer Impurities and Enable Reliable Clinical Supply.
LgRNA moves the critical control of spacer fidelity upstream to a short, readily purifiable fragment (<40nt) and decouples scaffold production from guide-specific synthesis. This architecture directly mitigates the spacer-impurity and lot-to-lot variability problems inherent in conventional long sgRNA, while remaining compatible with standard oligonucleotide quality requirements and enabling practical large-lot supply for rare-disease programs. The resulting product is both safer by design and more scalable.
Read more here.



Leave a Reply